Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters








Database
Language
Publication year range
1.
Biochem Biophys Res Commun ; 464(1): 299-305, 2015 Aug 14.
Article in English | MEDLINE | ID: mdl-26116772

ABSTRACT

Stem and progenitor cells are currently being investigated for their applicability in cell-based therapy for periodontal tissue regeneration. We recently demonstrated that the transplantation of adipose tissue-derived multi-lineage progenitor cells (ADMPCs) enhances periodontal tissue regeneration in beagle dogs. However, the molecular mechanisms by which transplanted ADMPCs induce periodontal tissue regeneration remain to be elucidated. In this study, trophic factors released by ADMPCs were examined for their paracrine effects on human periodontal ligament cell (HPDL) function. ADMPC conditioned medium (ADMPC-CM) up-regulated osteoblastic gene expression, alkaline phosphatase activity and calcified nodule formation in HPDLs, but did not significantly affect their proliferative response. ADMPCs secreted a number of growth factors, including insulin-like growth factor binding protein 6 (IGFBP6), hepatocyte growth factor and vascular endothelial growth factor. Among these, IGFBP6 was most highly expressed. Interestingly, the positive effects of ADMPC-CM on HPDL differentiation were significantly suppressed by transfecting ADMPCs with IGFBP6 siRNA. Our results suggest that ADMPCs transplanted into a defect in periodontal tissue release trophic factors that can stimulate the differentiation of HPDLs to mineralized tissue-forming cells, such as osteoblasts and cementoblasts. IGFBP6 may play crucial roles in ADMPC-induced periodontal regeneration.


Subject(s)
Adipose Tissue/cytology , Culture Media, Conditioned/pharmacology , Dental Cementum/drug effects , Osteoblasts/drug effects , Periodontal Ligament/drug effects , Stem Cells/cytology , Adipose Tissue/metabolism , Alkaline Phosphatase/genetics , Alkaline Phosphatase/metabolism , Cell Differentiation/drug effects , Cell Lineage/drug effects , Cells, Cultured , Dental Cementum/cytology , Dental Cementum/metabolism , Gene Expression Regulation , Hepatocyte Growth Factor/genetics , Hepatocyte Growth Factor/metabolism , Humans , Insulin-Like Growth Factor Binding Protein 6/antagonists & inhibitors , Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor Binding Protein 6/metabolism , Osteoblasts/cytology , Osteoblasts/metabolism , Osteogenesis/drug effects , Periodontal Ligament/cytology , Periodontal Ligament/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Signal Transduction , Stem Cells/metabolism , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/metabolism
2.
Mech Ageing Dev ; 132(10): 468-79, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21820463

ABSTRACT

Cellular senescence can be induced by a variety of mechanisms, and recent data suggest a key role for cytokine networks to maintain the senescent state. Here, we have used a proteomic LC-MS/MS approach to identify new extracellular regulators of senescence in human fibroblasts. We identified 26 extracellular proteins with significantly different abundance in conditioned media from young and senescent fibroblasts. Among these was insulin-like growth factor binding protein-6 (IGFBP-6), which was chosen for further analysis. When IGFBP-6 gene expression was downregulated, cell proliferation was inhibited and apoptotic cell death was increased. Furthermore, downregulation of IGFBP-6 led to premature entry into cellular senescence. Since IGFBP-6 overexpression increased cellular lifespan, the data suggest that IGFBP-6, in contrast to other IGF binding proteins, is a negative regulator of cellular senescence in human fibroblasts.


Subject(s)
Cellular Senescence/physiology , Insulin-Like Growth Factor Binding Protein 6/physiology , Adult , Aged , Aging/blood , Amino Acid Sequence , Apoptosis/genetics , Apoptosis/physiology , Base Sequence , Cell Proliferation , Cell Survival/genetics , Cell Survival/physiology , Cells, Cultured , Cellular Senescence/genetics , DNA Primers/genetics , Down-Regulation , Fibroblasts/cytology , Fibroblasts/physiology , Gene Knockdown Techniques , Humans , Insulin-Like Growth Factor Binding Protein 6/antagonists & inhibitors , Insulin-Like Growth Factor Binding Protein 6/genetics , Molecular Sequence Data , RNA, Small Interfering/genetics , Real-Time Polymerase Chain Reaction , Up-Regulation
3.
Oncogene ; 27(51): 6581-9, 2008 Nov 20.
Article in English | MEDLINE | ID: mdl-18985860

ABSTRACT

SEMA3B, a member of class 3 semaphorins, is a tumor suppressor. Competition with vascular endothelial growth factor (VEGF)165 explains a portion of the activity, whereas the VEGF-independent mechanism was not elucidated. We employed a microarray and screened for the genes whose expression was increased by SEMA3B in NCI-H1299 cells. Insulin-like growth factor-binding protein-6 (IGFBP-6), a tumor suppressor, showed greatest difference in the expression level. Introduction of IGFBP-6 cDNA reduced colony formation both on the dish surface and in soft agar. Insulin-like growth factor II, which antagonizes IGFBP-6, partly abrogated the effect. Inhibition of IGFBP-6 by small interfering RNA diminished the sub-G0/G1 population that was induced by SEMA3B and abrogated the growth suppressive effect of SEMA3B. We concluded that IGFBP-6 is the effector of tumor suppressor activity of SEMA3B in NCI-H1299 cells. It has been reported that beta-catenin suppresses the expression of IGFBP-6. Introduction of beta-catenin into the cells partly abrogated the growth suppressive effect of SEMA3B. Our result indicates that semaphorin signaling and beta-catenin signaling converge on IGFBP-6 and antithetically affect their functions.


Subject(s)
Insulin-Like Growth Factor Binding Protein 6/physiology , Membrane Glycoproteins/physiology , Semaphorins/physiology , Tumor Suppressor Proteins/physiology , Cell Proliferation/drug effects , Cells, Cultured , Humans , Insulin-Like Growth Factor Binding Protein 6/antagonists & inhibitors , Insulin-Like Growth Factor Binding Protein 6/genetics , Membrane Glycoproteins/genetics , Membrane Glycoproteins/metabolism , Protein Binding , RNA, Small Interfering/pharmacology , Semaphorins/genetics , Semaphorins/metabolism , Signal Transduction/drug effects , TCF Transcription Factors/metabolism , Transfection , Tumor Stem Cell Assay , Tumor Suppressor Proteins/metabolism , beta Catenin/metabolism
4.
J Gastroenterol Hepatol ; 17(5): 563-70, 2002 May.
Article in English | MEDLINE | ID: mdl-12084030

ABSTRACT

BACKGROUND: : Previously, we have observed that highly unsaturated dietary (n-3) fatty acids inhibit cell proliferation in conjunction with stimulation of insulin-like growth factor-binding protein (IGFBP)-6 secretion in Caco-2 cells, a human colon carcinoma cell line. METHODS: : To test the converse hypothesis that inhibition of endogenous IGFBP-6 secretion stimulates Caco-2 cell proliferation, cells were transfected with the antisense IGFBP-6 expression construct or pcDNA3 vector only, and single colonies resistant to G418 sulfate were isolated. RESULTS: : Our initial studies indicated that three antisense clones grew faster and produced less IGFBP-6 than two pcDNA3 clones, so antisense IGFBP-6 #5 and pcDNA3 #8 were selected for further detailed analysis. Both the control and antisense clones grew in serum-free medium reaching a plateau density at day eight. However, the antisense clone grew at a rate faster than that of the control and reached a final density that was 31 +/- 3% higher than the control. Northern blot, ligand blot and immunoblot analyses revealed that accumulation of IGFBP-6 mRNA and concentrations of IGFBP-6 peptide produced by the antisense clone were decreased by 80-90% compared to the control. The doubling times of the antisense and control clones were 21.9 +/- 0.4 and 24.8 +/- 0.3 h (P < 0.05), respectively. Exogenous IGF-I and IGF-II (0.2-200 nmol/L) stimulated proliferation of both the control and antisense clones in a dose-dependent manner, but the relative potency and efficacy of IGF-II was higher in the antisense clone compared to the control. These results indicate that suppression of IGFBP-6 secretion correlates with an increase in the basal rate of Caco-2 cell growth. CONCLUSIONS: : Our findings are consistent with the hypothesis that IGFBP-6 inhibits cell growth by binding to endogenously produced IGF-II, thereby preventing IGF-II from interacting with the IGF-I receptor to stimulate cellular proliferation by an autocrine mechanism.


Subject(s)
Colonic Neoplasms/pathology , Insulin-Like Growth Factor Binding Protein 6/antagonists & inhibitors , Oligonucleotides, Antisense/pharmacology , Caco-2 Cells , Cell Count , Cell Division/drug effects , DNA, Complementary/genetics , Humans , Insulin-Like Growth Factor Binding Protein 6/genetics , Insulin-Like Growth Factor I/pharmacology , Insulin-Like Growth Factor II/pharmacology , RNA, Messenger/antagonists & inhibitors , Time Factors , Transfection
5.
Growth Horm IGF Res ; 11(6): 368-77, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11914024

ABSTRACT

All-trans -retinoic acid (atRA) inhibits osteoblast marker gene expression and markedly increases expression of insulin-like growth factor binding protein-6 (IGFBP-6) in human osteoblasts. The possibility that IGFBP-6 inhibits the osteoblast phenotype and also mediates the inhibitory effect of atRA on osteoblast marker gene expression was explored using an antisense approach. Stable human osteoblast-like osteosarcoma SaOS-2 cells were prepared that expressed antisense IGFBP-6 RNA under basal and atRA-stimulated conditions. The functional expression of IGFBP-6 antisense RNA was confirmed by measuring IGFBP-6 mRNA by Northern analysis or by measuring IGFBP-6 protein in the conditioned media (CM) by radioimmunoassay. Antisense clones produced less mRNA and had less IGFBP-6 protein in the CM than controls. IGFBP-6 protein levels in the CM were inversely correlated with alkaline phosphatase (ALP) activity, whereas IGFBP-3 and IGFBP-4 protein levels were not. We reasoned that atRA would have little or no effect on ALP activity in IGFBP-6 antisense clones if atRA mediated its inhibitory effects by recruiting IGFBP-6. In the majority of IGFBP-6 antisense clones with the lowest IGFBP-6 mRNA and CM protein levels and only modest changes in other IGF system components, atRA did not significantly decrease ALP activity. These findings provide evidence that atRA recruits IGFBP-6 to inhibit the human osteoblast phenotype.


Subject(s)
Insulin-Like Growth Factor Binding Protein 6/metabolism , Osteoblasts/drug effects , Osteoblasts/metabolism , Tretinoin/pharmacology , Alkaline Phosphatase/metabolism , Cell Differentiation/drug effects , Cell Division/drug effects , Cell Line , DNA, Antisense/pharmacology , Gene Expression/drug effects , Genetic Markers , Humans , Insulin-Like Growth Factor Binding Protein 6/antagonists & inhibitors , Insulin-Like Growth Factor Binding Protein 6/genetics , Osteoblasts/cytology , Phenotype , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL